Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFM 2020-02 MRD-adapted frontline therapy in transplant-eligible newly diagnosed multiple myeloma
2024-513889-19-00Phase 3Authorised
- Sponsor
- Inter-Groupe Francophone du Myélome
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of isatuximab, carfilzomib, lenalidomide, iberdomide and dexamethasone in multiple myeloma (MM) (4 arms), sponsored by Inter-Groupe Francophone du Myélome. Primary endpoint: MRD negativity before maintenance. Planned start Nov 2024; status: authorised.
02
Drugs
isatuximabcarfilzomiblenalidomideiberdomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-513889-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513889-19-00.